Home > Boards > US OTC > Biotechs > Nutra Pharma Corp. (NPHC)

Next few weeks I expect 10-k and AS

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
gempicker Member Profile
 
Followed By 91
Posts 13,433
Boards Moderated 0
Alias Born 06/02/04
160x600 placeholder
gempicker   Saturday, 03/31/18 11:20:52 AM
Re: None
Post # of 43187 
Next few weeks I expect 10-k and AS raise as officially done. From there there will probably be a little dilution as debt is consolidated and some financing is probably necessary to move company forward. I expect this not to be death spiral dilution, in fact I believe the financiers will have incentive to see pps rise significantly..

Meanwhile a PR campaign logically should initiate. Tell us about manufacturing, U of Maryland success, GSA and government sales beginning; incremental revenues and retail rollout plans.

Hopefully tell us about funding package to get phase 2 clinicals rolling for MS pediatric. Tell us if you plan to pursue government grants and funding that is coming available to fight opiods. These funds could be all that is needed to strengthen Nyloxin case as a significant tool to fight pain, etc..

Nobody is denying the product, nor the potential. We just need a methodical structured approach and watch market valuations quickly rise to 20,30,50 million as success is achieved. Whether there is 2,2.5, or 3 Billion shares out won’t matter much as the stock surpasses .01 and sales and clinical pipelines have momentum. Optimism will be high and 100 or 200 million valuations will seem and realistically be more achievable in the following year..

Everyone wins: the company, the financiers, shareholders and most importantly the people who desperately need real solutions to medical issues.

Be methodical.. be patient.. be successful..

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist